Crossmark

Incident Kaposi sarcoma during the expansion of antiretroviral therapy eligibility in Nigeria: a retrospective cohort study

Crossref DOI link: https://doi.org/10.1186/s12885-023-11402-3

Published Online: 2023-09-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Akanbi, Maxwell. O.

Bilaver, Lucy. A.

Achenbach, Chad

Hirschhorn, Lisa. R.

Rivera, Adovich. S.

Adekolujo, Orimisan. S.

Adekola, Kehinde. U. A.

Silas, Olugbenga. A.

Agaba, Patricia. A.

Agbaji, Oche

Shehu, Nathan. Y.

Sagay, Solomon. A.

Hou, Lifang

Murphy, Robert. L.
Funding

Funding for this research was provided by:

John E. Fogarty International Center (5D43TW009575-05, 5D43TW009575-05, 5D43TW009575-05)

US Department of Health and Human Services (U51HA02522, U51HA02522, U51HA02522, U51HA02522)

Centers for Disease Control and Prevention (PS 001058, PS 001058, PS 001058)

National Cancer Institute (1U54CA221205-01, 1U54CA221205-01)
License Information

Text and Data Mining valid from 2023-09-21

Version of Record valid from 2023-09-21
More Information

Article History

Received: 26 January 2023

Accepted: 13 September 2023

First Online: 21 September 2023

Declarations

:

: The study was conducted in accordance with the Declaration of Helsinki.We obtained Institutional Review Board approval from the JUTH Research and Ethics Committee (JUTH/DCS/ADM/127/XXVII/715) and the study was ruled exempt by the Institutional Review Board of Northwestern University, Chicago, USA (STU00209667). Permission for secondary data use was obtained from the APIN regulatory affairs committee, Nigeria (ARA/2018/001), and the Harvard T. Chan School of Public Health. All study participants in the Harvard/APIN PEPFAR program provided informed consent for the use of their data and/or samples for research.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below